Review



v600e mutant  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Addgene inc v600e mutant
    ( A ) Silencing efficiency of four perfect-match, BRAF -targeting crRNAs at 48 hours after knock-in of WT (gray) or <t>V600E</t> (purple BRAF variants, normalized against crNT. ( B ) Systematic mutagenesis of nonselective cr BRAF -1 was used to engineer V600E -selective crRNAs. Sequences for each crRNA are shown below the bar plot; the “U” nucleotide (in red) indicates the uracil in the spacer sequence that base pairs with the target V600E but not with the WT BRAF RNA, and the colored nucleotides show the position of an additional mismatch introduced at various spacer locations through mutagenesis. Bar plot shows the silencing efficiency of cr BRAF -1 and its mutagenesis derivatives against BRAF - WT (gray) versus BRAF - V600E (purple), normalized against crNT at 48 hours after transfection. crE 5 -MM 8,15 and crE 5 -MM 11,15 (orange arrows) show the highest selectivity against BRAF V600E . ( C ) Delta silencing efficiencies between WT (gray) and V600E (purple) variants for the top-performing crRNAs, indicating the degree of SNV-specificity. Schematics depicting the sequence and base-pairing configuration of crE 5 -MM 8,15 and crE 5 -MM 11,15 with WT versus V600E -mutant BRAF mRNA targets are shown adjacent. ( D ) Dose-response curves derived from titration of parental cr BRAF -1, crE 5 -MM 8,15 , and crE 5 -MM 11,15 against WT (gray) or V600E (purple) BRAF at 48 hours after transfection. For all graphs in (A) to (C), individual data points show averaged fluorescence intensity from eight representative fields of view ( n = 3 independent experiments), and error bars show means ± SD. ( E ) Silencing efficiency assessed by Western blotting in HEK293T cells transfected with Psp Cas13b and full-length WT or SNV constructs. ( F ) Silencing efficiency assessed by RT-qPCR in cancer cell lines (A375 melanoma and HCT116 colorectal cancer), which endogenously express the SNV-containing oncogene (means ± SD from n = 3 independent experiments). Statistical significance was determined using unpaired t tests, where ** P < 0.01, *** P < 0.001, and **** P < 0.0001.
    V600e Mutant, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/v600e mutant/product/Addgene inc
    Average 92 stars, based on 3 article reviews
    v600e mutant - by Bioz Stars, 2026-06
    92/100 stars

    Images

    1) Product Images from "Principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision"

    Article Title: Principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision

    Journal: Science Advances

    doi: 10.1126/sciadv.adl0731

    ( A ) Silencing efficiency of four perfect-match, BRAF -targeting crRNAs at 48 hours after knock-in of WT (gray) or V600E (purple BRAF variants, normalized against crNT. ( B ) Systematic mutagenesis of nonselective cr BRAF -1 was used to engineer V600E -selective crRNAs. Sequences for each crRNA are shown below the bar plot; the “U” nucleotide (in red) indicates the uracil in the spacer sequence that base pairs with the target V600E but not with the WT BRAF RNA, and the colored nucleotides show the position of an additional mismatch introduced at various spacer locations through mutagenesis. Bar plot shows the silencing efficiency of cr BRAF -1 and its mutagenesis derivatives against BRAF - WT (gray) versus BRAF - V600E (purple), normalized against crNT at 48 hours after transfection. crE 5 -MM 8,15 and crE 5 -MM 11,15 (orange arrows) show the highest selectivity against BRAF V600E . ( C ) Delta silencing efficiencies between WT (gray) and V600E (purple) variants for the top-performing crRNAs, indicating the degree of SNV-specificity. Schematics depicting the sequence and base-pairing configuration of crE 5 -MM 8,15 and crE 5 -MM 11,15 with WT versus V600E -mutant BRAF mRNA targets are shown adjacent. ( D ) Dose-response curves derived from titration of parental cr BRAF -1, crE 5 -MM 8,15 , and crE 5 -MM 11,15 against WT (gray) or V600E (purple) BRAF at 48 hours after transfection. For all graphs in (A) to (C), individual data points show averaged fluorescence intensity from eight representative fields of view ( n = 3 independent experiments), and error bars show means ± SD. ( E ) Silencing efficiency assessed by Western blotting in HEK293T cells transfected with Psp Cas13b and full-length WT or SNV constructs. ( F ) Silencing efficiency assessed by RT-qPCR in cancer cell lines (A375 melanoma and HCT116 colorectal cancer), which endogenously express the SNV-containing oncogene (means ± SD from n = 3 independent experiments). Statistical significance was determined using unpaired t tests, where ** P < 0.01, *** P < 0.001, and **** P < 0.0001.
    Figure Legend Snippet: ( A ) Silencing efficiency of four perfect-match, BRAF -targeting crRNAs at 48 hours after knock-in of WT (gray) or V600E (purple BRAF variants, normalized against crNT. ( B ) Systematic mutagenesis of nonselective cr BRAF -1 was used to engineer V600E -selective crRNAs. Sequences for each crRNA are shown below the bar plot; the “U” nucleotide (in red) indicates the uracil in the spacer sequence that base pairs with the target V600E but not with the WT BRAF RNA, and the colored nucleotides show the position of an additional mismatch introduced at various spacer locations through mutagenesis. Bar plot shows the silencing efficiency of cr BRAF -1 and its mutagenesis derivatives against BRAF - WT (gray) versus BRAF - V600E (purple), normalized against crNT at 48 hours after transfection. crE 5 -MM 8,15 and crE 5 -MM 11,15 (orange arrows) show the highest selectivity against BRAF V600E . ( C ) Delta silencing efficiencies between WT (gray) and V600E (purple) variants for the top-performing crRNAs, indicating the degree of SNV-specificity. Schematics depicting the sequence and base-pairing configuration of crE 5 -MM 8,15 and crE 5 -MM 11,15 with WT versus V600E -mutant BRAF mRNA targets are shown adjacent. ( D ) Dose-response curves derived from titration of parental cr BRAF -1, crE 5 -MM 8,15 , and crE 5 -MM 11,15 against WT (gray) or V600E (purple) BRAF at 48 hours after transfection. For all graphs in (A) to (C), individual data points show averaged fluorescence intensity from eight representative fields of view ( n = 3 independent experiments), and error bars show means ± SD. ( E ) Silencing efficiency assessed by Western blotting in HEK293T cells transfected with Psp Cas13b and full-length WT or SNV constructs. ( F ) Silencing efficiency assessed by RT-qPCR in cancer cell lines (A375 melanoma and HCT116 colorectal cancer), which endogenously express the SNV-containing oncogene (means ± SD from n = 3 independent experiments). Statistical significance was determined using unpaired t tests, where ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

    Techniques Used: Knock-In, Mutagenesis, Sequencing, Transfection, Derivative Assay, Titration, Fluorescence, Western Blot, Construct, Quantitative RT-PCR



    Similar Products

    96
    ATCC braf v600e mutant colo
    Braf V600e Mutant Colo, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/braf v600e mutant colo/product/ATCC
    Average 96 stars, based on 1 article reviews
    braf v600e mutant colo - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    93
    Cell Signaling Technology Inc anti foxa1
    Anti Foxa1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti foxa1/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    anti foxa1 - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    93
    BPS Bioscience v600e mutant kinase assay kit catalog number 48688
    V600e Mutant Kinase Assay Kit Catalog Number 48688, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/v600e mutant kinase assay kit catalog number 48688/product/BPS Bioscience
    Average 93 stars, based on 1 article reviews
    v600e mutant kinase assay kit catalog number 48688 - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    93
    Cell Signaling Technology Inc bovine serum albumin
    Bovine Serum Albumin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bovine serum albumin/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    bovine serum albumin - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    93
    Cell Signaling Technology Inc incubation with brafve
    Incubation With Brafve, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/incubation with brafve/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    incubation with brafve - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    90
    Arvinas Inc braf v600e mutants
    Braf V600e Mutants, supplied by Arvinas Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/braf v600e mutants/product/Arvinas Inc
    Average 90 stars, based on 1 article reviews
    braf v600e mutants - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    92
    Addgene inc v600e mutant
    ( A ) Silencing efficiency of four perfect-match, BRAF -targeting crRNAs at 48 hours after knock-in of WT (gray) or <t>V600E</t> (purple BRAF variants, normalized against crNT. ( B ) Systematic mutagenesis of nonselective cr BRAF -1 was used to engineer V600E -selective crRNAs. Sequences for each crRNA are shown below the bar plot; the “U” nucleotide (in red) indicates the uracil in the spacer sequence that base pairs with the target V600E but not with the WT BRAF RNA, and the colored nucleotides show the position of an additional mismatch introduced at various spacer locations through mutagenesis. Bar plot shows the silencing efficiency of cr BRAF -1 and its mutagenesis derivatives against BRAF - WT (gray) versus BRAF - V600E (purple), normalized against crNT at 48 hours after transfection. crE 5 -MM 8,15 and crE 5 -MM 11,15 (orange arrows) show the highest selectivity against BRAF V600E . ( C ) Delta silencing efficiencies between WT (gray) and V600E (purple) variants for the top-performing crRNAs, indicating the degree of SNV-specificity. Schematics depicting the sequence and base-pairing configuration of crE 5 -MM 8,15 and crE 5 -MM 11,15 with WT versus V600E -mutant BRAF mRNA targets are shown adjacent. ( D ) Dose-response curves derived from titration of parental cr BRAF -1, crE 5 -MM 8,15 , and crE 5 -MM 11,15 against WT (gray) or V600E (purple) BRAF at 48 hours after transfection. For all graphs in (A) to (C), individual data points show averaged fluorescence intensity from eight representative fields of view ( n = 3 independent experiments), and error bars show means ± SD. ( E ) Silencing efficiency assessed by Western blotting in HEK293T cells transfected with Psp Cas13b and full-length WT or SNV constructs. ( F ) Silencing efficiency assessed by RT-qPCR in cancer cell lines (A375 melanoma and HCT116 colorectal cancer), which endogenously express the SNV-containing oncogene (means ± SD from n = 3 independent experiments). Statistical significance was determined using unpaired t tests, where ** P < 0.01, *** P < 0.001, and **** P < 0.0001.
    V600e Mutant, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/v600e mutant/product/Addgene inc
    Average 92 stars, based on 1 article reviews
    v600e mutant - by Bioz Stars, 2026-06
    92/100 stars
      Buy from Supplier

    93
    Cell Signaling Technology Inc immunostains like brafv600e
    ( A ) Silencing efficiency of four perfect-match, BRAF -targeting crRNAs at 48 hours after knock-in of WT (gray) or <t>V600E</t> (purple BRAF variants, normalized against crNT. ( B ) Systematic mutagenesis of nonselective cr BRAF -1 was used to engineer V600E -selective crRNAs. Sequences for each crRNA are shown below the bar plot; the “U” nucleotide (in red) indicates the uracil in the spacer sequence that base pairs with the target V600E but not with the WT BRAF RNA, and the colored nucleotides show the position of an additional mismatch introduced at various spacer locations through mutagenesis. Bar plot shows the silencing efficiency of cr BRAF -1 and its mutagenesis derivatives against BRAF - WT (gray) versus BRAF - V600E (purple), normalized against crNT at 48 hours after transfection. crE 5 -MM 8,15 and crE 5 -MM 11,15 (orange arrows) show the highest selectivity against BRAF V600E . ( C ) Delta silencing efficiencies between WT (gray) and V600E (purple) variants for the top-performing crRNAs, indicating the degree of SNV-specificity. Schematics depicting the sequence and base-pairing configuration of crE 5 -MM 8,15 and crE 5 -MM 11,15 with WT versus V600E -mutant BRAF mRNA targets are shown adjacent. ( D ) Dose-response curves derived from titration of parental cr BRAF -1, crE 5 -MM 8,15 , and crE 5 -MM 11,15 against WT (gray) or V600E (purple) BRAF at 48 hours after transfection. For all graphs in (A) to (C), individual data points show averaged fluorescence intensity from eight representative fields of view ( n = 3 independent experiments), and error bars show means ± SD. ( E ) Silencing efficiency assessed by Western blotting in HEK293T cells transfected with Psp Cas13b and full-length WT or SNV constructs. ( F ) Silencing efficiency assessed by RT-qPCR in cancer cell lines (A375 melanoma and HCT116 colorectal cancer), which endogenously express the SNV-containing oncogene (means ± SD from n = 3 independent experiments). Statistical significance was determined using unpaired t tests, where ** P < 0.01, *** P < 0.001, and **** P < 0.0001.
    Immunostains Like Brafv600e, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/immunostains like brafv600e/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    immunostains like brafv600e - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    90
    Spring Bioscience braf-v600e mutant-specific antibody ve1
    ( A ) Silencing efficiency of four perfect-match, BRAF -targeting crRNAs at 48 hours after knock-in of WT (gray) or <t>V600E</t> (purple BRAF variants, normalized against crNT. ( B ) Systematic mutagenesis of nonselective cr BRAF -1 was used to engineer V600E -selective crRNAs. Sequences for each crRNA are shown below the bar plot; the “U” nucleotide (in red) indicates the uracil in the spacer sequence that base pairs with the target V600E but not with the WT BRAF RNA, and the colored nucleotides show the position of an additional mismatch introduced at various spacer locations through mutagenesis. Bar plot shows the silencing efficiency of cr BRAF -1 and its mutagenesis derivatives against BRAF - WT (gray) versus BRAF - V600E (purple), normalized against crNT at 48 hours after transfection. crE 5 -MM 8,15 and crE 5 -MM 11,15 (orange arrows) show the highest selectivity against BRAF V600E . ( C ) Delta silencing efficiencies between WT (gray) and V600E (purple) variants for the top-performing crRNAs, indicating the degree of SNV-specificity. Schematics depicting the sequence and base-pairing configuration of crE 5 -MM 8,15 and crE 5 -MM 11,15 with WT versus V600E -mutant BRAF mRNA targets are shown adjacent. ( D ) Dose-response curves derived from titration of parental cr BRAF -1, crE 5 -MM 8,15 , and crE 5 -MM 11,15 against WT (gray) or V600E (purple) BRAF at 48 hours after transfection. For all graphs in (A) to (C), individual data points show averaged fluorescence intensity from eight representative fields of view ( n = 3 independent experiments), and error bars show means ± SD. ( E ) Silencing efficiency assessed by Western blotting in HEK293T cells transfected with Psp Cas13b and full-length WT or SNV constructs. ( F ) Silencing efficiency assessed by RT-qPCR in cancer cell lines (A375 melanoma and HCT116 colorectal cancer), which endogenously express the SNV-containing oncogene (means ± SD from n = 3 independent experiments). Statistical significance was determined using unpaired t tests, where ** P < 0.01, *** P < 0.001, and **** P < 0.0001.
    Braf V600e Mutant Specific Antibody Ve1, supplied by Spring Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/braf-v600e mutant-specific antibody ve1/product/Spring Bioscience
    Average 90 stars, based on 1 article reviews
    braf-v600e mutant-specific antibody ve1 - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) Silencing efficiency of four perfect-match, BRAF -targeting crRNAs at 48 hours after knock-in of WT (gray) or V600E (purple BRAF variants, normalized against crNT. ( B ) Systematic mutagenesis of nonselective cr BRAF -1 was used to engineer V600E -selective crRNAs. Sequences for each crRNA are shown below the bar plot; the “U” nucleotide (in red) indicates the uracil in the spacer sequence that base pairs with the target V600E but not with the WT BRAF RNA, and the colored nucleotides show the position of an additional mismatch introduced at various spacer locations through mutagenesis. Bar plot shows the silencing efficiency of cr BRAF -1 and its mutagenesis derivatives against BRAF - WT (gray) versus BRAF - V600E (purple), normalized against crNT at 48 hours after transfection. crE 5 -MM 8,15 and crE 5 -MM 11,15 (orange arrows) show the highest selectivity against BRAF V600E . ( C ) Delta silencing efficiencies between WT (gray) and V600E (purple) variants for the top-performing crRNAs, indicating the degree of SNV-specificity. Schematics depicting the sequence and base-pairing configuration of crE 5 -MM 8,15 and crE 5 -MM 11,15 with WT versus V600E -mutant BRAF mRNA targets are shown adjacent. ( D ) Dose-response curves derived from titration of parental cr BRAF -1, crE 5 -MM 8,15 , and crE 5 -MM 11,15 against WT (gray) or V600E (purple) BRAF at 48 hours after transfection. For all graphs in (A) to (C), individual data points show averaged fluorescence intensity from eight representative fields of view ( n = 3 independent experiments), and error bars show means ± SD. ( E ) Silencing efficiency assessed by Western blotting in HEK293T cells transfected with Psp Cas13b and full-length WT or SNV constructs. ( F ) Silencing efficiency assessed by RT-qPCR in cancer cell lines (A375 melanoma and HCT116 colorectal cancer), which endogenously express the SNV-containing oncogene (means ± SD from n = 3 independent experiments). Statistical significance was determined using unpaired t tests, where ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

    Journal: Science Advances

    Article Title: Principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision

    doi: 10.1126/sciadv.adl0731

    Figure Lengend Snippet: ( A ) Silencing efficiency of four perfect-match, BRAF -targeting crRNAs at 48 hours after knock-in of WT (gray) or V600E (purple BRAF variants, normalized against crNT. ( B ) Systematic mutagenesis of nonselective cr BRAF -1 was used to engineer V600E -selective crRNAs. Sequences for each crRNA are shown below the bar plot; the “U” nucleotide (in red) indicates the uracil in the spacer sequence that base pairs with the target V600E but not with the WT BRAF RNA, and the colored nucleotides show the position of an additional mismatch introduced at various spacer locations through mutagenesis. Bar plot shows the silencing efficiency of cr BRAF -1 and its mutagenesis derivatives against BRAF - WT (gray) versus BRAF - V600E (purple), normalized against crNT at 48 hours after transfection. crE 5 -MM 8,15 and crE 5 -MM 11,15 (orange arrows) show the highest selectivity against BRAF V600E . ( C ) Delta silencing efficiencies between WT (gray) and V600E (purple) variants for the top-performing crRNAs, indicating the degree of SNV-specificity. Schematics depicting the sequence and base-pairing configuration of crE 5 -MM 8,15 and crE 5 -MM 11,15 with WT versus V600E -mutant BRAF mRNA targets are shown adjacent. ( D ) Dose-response curves derived from titration of parental cr BRAF -1, crE 5 -MM 8,15 , and crE 5 -MM 11,15 against WT (gray) or V600E (purple) BRAF at 48 hours after transfection. For all graphs in (A) to (C), individual data points show averaged fluorescence intensity from eight representative fields of view ( n = 3 independent experiments), and error bars show means ± SD. ( E ) Silencing efficiency assessed by Western blotting in HEK293T cells transfected with Psp Cas13b and full-length WT or SNV constructs. ( F ) Silencing efficiency assessed by RT-qPCR in cancer cell lines (A375 melanoma and HCT116 colorectal cancer), which endogenously express the SNV-containing oncogene (means ± SD from n = 3 independent experiments). Statistical significance was determined using unpaired t tests, where ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

    Article Snippet: Plasmids encoding full-length BRAF WT (p3xFLAG-CMV- BRAF , Addgene #131710) and V600E mutant (p3xFLAG-CMV- BRAF - V600E , Addgene #131723) were gifts from J.

    Techniques: Knock-In, Mutagenesis, Sequencing, Transfection, Derivative Assay, Titration, Fluorescence, Western Blot, Construct, Quantitative RT-PCR